An underground market for unlicensed slimming drugs is propelled by social media fitness personalities and sellers on communication apps, based on new investigations.
Investigational Drug Gaining Popularity Online
The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged weight-reducing effects. Followers are encouraged to contact these profiles privately for supplier links, while also receiving discount codes.
Active Trade on Messaging Platforms
Additionally, a robust market exists on messaging services, where communities with numerous of members share “before and after” photos, injection guides and claims of next-day UK delivery. Vendors promote the drug there before directing buyers to WhatsApp for purchases.
Understanding Retatrutide
Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help individuals lose up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed digitally as the next Ozempic.
Healthcare Professionals Voice Concerns
However, physicians and pharmacists have cautions that the sale of what remains an unlicensed drug in the United Kingdom is worrisome and could result in users injecting substances of uncertain source.
Several experts stated the popularity for retatrutide could be linked to the rising cost of approved weight loss treatments such as Mounjaro.
Legal Status and Implementation
Selling the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved drug that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.
Some influencers attempt to circumvent the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and supply can still breach medicines, advertising, and consumer regulations, risking fines, legal action or prison.
Service Reaction and Content Removal
According to the social media company, the service has taken down problematic content and prohibited related keywords and search suggestions. The company stated it was committed to keeping the platform safe and allocating resources in strengthening compliance measures.
Online Trading Activities
Investigations also found groups with up to nine thousand participants selling the experimental drug using the platform's built-in search feature, which functions like a public directory. Typing “retatrutide” instantly displays groups with thousands of users, populated with photos of slimming results, positive testimonials and detailed instructions for mixing or administering at residence.
After moments of entering one community, a vendor posted contact information, where most transactions take place. The vendor sent an instruction manual and promised shipping within two days. When questioned whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. Not one asked about body mass, medical conditions or past usage.
Item Information and Pricing
Inside these communities, posts display black plastic packages with Royal Mail labels, stating to contain new batches. One message stated: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, mixed at home with sterile water, or ready-to-use injectors usually priced at 160 pounds for 20 milligrams. When asked how long a injector should last, sellers give conflicting responses ranging from a few weeks to “depends on your body”.
Platform Moderation and Security Measures
A representative for Telegram stated it actively monitored harmful content on its platform including material that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“People are administering substances they cannot confirm. Although the research behind this drug is valid, these digital versions may not contain what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U.
A medical professional of Asda Online Doctor linked the increase in interest to current cost increases for approved slimming medications such as Mounjaro. “With prices increasing, patients are using online platforms. But counterfeit treatments are highly risky. You can’t be certain what’s contained or whether the environment they were produced in was clean,” she explained.
Her staff has already seen individuals harmed by personal administration from unconfirmed sources. “We recognize the frustration, but buying from Telegram or WhatsApp is gambling with your well-being,” stated the doctor. “These materials could be contaminated or improperly measured.”
Producer Position
A spokesperson from the pharmaceutical company said the substance was in phase 3 research studies and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they explained, noting that any product “misleadingly claiming itself as a Lilly investigational substance not yet authorized … may subject patients to possibly serious health risks”.
